Sex-specific considerations in nanomedicine: highlighting the impact of the menstrual cycle on drug development.
clinical trials
drug development
hormonal changes
menstrual cycle
nanomedicine
nanoparticles
protein corona
sex differences
sex-specific analysis
women's health
Journal
Nanomedicine (London, England)
ISSN: 1748-6963
Titre abrégé: Nanomedicine (Lond)
Pays: England
ID NLM: 101278111
Informations de publication
Date de publication:
03 2024
03 2024
Historique:
medline:
12
3
2024
pubmed:
21
12
2023
entrez:
21
12
2023
Statut:
ppublish
Résumé
Tweetable abstract The female menstrual cycle is one of the most overlooked sex-specific factors in drug distribution and response. Unlocking the potential of nanomedicine demands a fundamental understanding of the impact biological sex has on drug distribution, efficacy and adverse effects.
Identifiants
pubmed: 38127525
doi: 10.2217/nnm-2023-0347
doi:
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM